Form 4: Nuvalent Officer Trades Class A Stock

Nuvalent, Inc. Chief Scientific Officer Henry E. Pelish reports transactions involving Class A Common Stock, including sales executed under a Rule 10b5-1 trading plan.

Summary

• Henry E. Pelish, Chief Scientific Officer of Nuvalent, Inc., reported several transactions on April 9, 2026.
• These transactions involved the acquisition of 3,093 shares of Class A Common Stock at a price of $27.85 per share, executed under a Rule 10b5-1 trading plan.
• Additionally, Pelish disposed of 2,193 shares at a weighted average price of $104.27 and 900 shares at a weighted average price of $105.
• Following these transactions, Pelish beneficially owns 66,504 shares directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of shares by a high-ranking executive, despite the presence of a Rule 10b5-1 plan.

Positives

• Acquisition of 3,093 shares at $27.85, potentially indicating a favorable entry point or part of a planned acquisition strategy.
• The transactions were executed under a Rule 10b5-1 trading plan, suggesting a pre-determined strategy for stock transactions, which can reduce concerns about insider trading.

Negatives

• Disposal of a significant number of shares (3,093 shares) at prices substantially higher than the acquisition price, indicating potential profit-taking by a key executive.
• The weighted average sale prices of $104.27 and $105 suggest a substantial gain for the disposed shares.

Risks

• The sale of shares by a Chief Scientific Officer could be interpreted by the market as a lack of confidence in future stock performance, although it was conducted under a Rule 10b5-1 plan.
• The significant difference between the acquisition price and sale prices might indicate that the stock has reached a peak in the executive's view.

Future Outlook

The filing does not contain forward-looking statements or guidance. The transactions are based on a pre-established trading plan.

Management Comments

• Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2025.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) upon request.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, can sometimes lead to short-term market reactions. However, the existence of the plan itself is designed to mitigate concerns about opportunistic trading.

Stakeholder Impact

• Shareholders may react to the sale of shares by a key executive, potentially leading to short-term stock price fluctuations.
• Employees may interpret the sale as a signal from management, though the Rule 10b5-1 plan mitigates this concern.

Next Steps

• The reporting person may continue to execute transactions under the Rule 10b5-1 trading plan.
• Nuvalent, Inc. may receive requests for detailed transaction information from the SEC or security holders.

Key Dates

Recommendation

The filing reports insider transactions, specifically sales by a Chief Scientific Officer under a Rule 10b5-1 plan. While the sale itself can be a negative signal, the pre-arranged plan suggests a strategic, rather than opportunistic, divestment. Without further financial or operational data from Nuvalent, Inc., a 'hold' recommendation is prudent, allowing for observation of market reaction and future company performance.

Keywords

Nuvalent, NUVL, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Class A Common Stock, Henry E. Pelish, Chief Scientific Officer, Beneficial Ownership